In March 2012, Columbia University announced the opening of the Center for Lymphoid Malignancies in New York City. The center’s focus is on the care of patients with the various forms of non-Hodgkin lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, and Hodgkin disease. The highly skilled and experienced staff at the center comprises more than 25 personnel, including physicians, nurses, clinical trial coordinators, regulatory specialists, laboratory scientists, and other support staff under the directorship of Owen A.
The surprising results of a randomized trial on patient preference for one cancer therapy over another show that patient-reported quality-of-life (QOL) differences influence treatment preference far more than physicians had imagined, suggested researchers at the 2012 Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois.
At the recent 2012 symposium of the Multinational As sociation of Supportive Care in Cancer (MASCC), held in New York City, experts discussed a wide range of topics related to management of treatmentinduced side effects. Below are some highlights from the MASCC annual symposium.
Management of Febrile Neutropenia
In this month’s issue of The Oncology Nurse-APN/PA (TON), we continue our coverage of the news from the 37th Annual Congress of the Oncology Nursing Society (ONS) and the 2012 Annual Meeting of the American Society of Clinical Oncology. The news from ONS continues to demonstrate the important role nurses play in symptom management and in helping patients prepare for and understand their treatments.
On August 3, 2012, the US Food and Drug Administration (FDA) approved ziv-aflibercept (Zaltrap, Sanofi US Inc) for use in combination with FOLFIRI (5-fluorouracil, leuco - vorin, and irinotecan) for the treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing chemotherapy regimen. Ziv-aflibercept, which was previously known as aflibercept, is an angiogenesis inhibitor that inhibits the blood supply to tumors.
The FDA approved everolimus (Afinitor; Novartis Pharmaceuticals Corporation) for use in combination with exemestane to treat postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer who experienced treatment failure with letrozole or anastrozole. The approval was granted on July 20, 2012.
I hate to criticize oncology nurses. I honestly appreciate the care they have given me and the difficulty of dealing constantly with seriously ill patients. Yet, on a recent hospital stay, my oncology nurses failed me. They treated my physical symptoms but completely left me hanging emotionally.
Each year, a significant number of adolescents and young adults (AYAs), aged 15 to 39 years, are faced with a cancer diagnosis—that’s more than 70,000 in the United States. Although cancer prognosis for AYAs has improved over recent decades, survival rates have not advanced at the same rate as other age groups. To better understand the facts and figures associated with these patients, let’s take a closer look at AYA oncology statistics.
A program conducted at Cedars-Sinai Medical Center, Los Angeles, California, improved oncology nurses’ awareness of dyspnea in patients with advanced cancer. Sarah Kang, RN, MSN, described the program at the 37th Annual Congress of the Oncology Nursing Society.
Results 1 - 10 of 13